Clinical Trial Update: A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder [Phase 2]

View source ↗

Summary

Phase II multicenter study comparing chemotherapy alone versus chemotherapy plus durvalumab (MEDI4736) in patients with lymph node–positive urothelial carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING